CART-immune-related adverse events after BCMA CAR-T therapy

Molecular Therapy: Oncology · Published 2026-07-02 · DOI 10.1016/j.omton.2026.201274

Free full text

Authors (7)

Luca Paruzzo, Matthew Ho, Julia Han Noll, Alfred L. Garfall, Adam D. Cohen, Joseph A. Fraietta, Marco Ruella

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Paruzzo, L., Ho, M., Noll, J., et al. (2026). CART-immune-related adverse events after BCMA CAR-T therapy. Molecular Therapy: Oncology. https://doi.org/10.1016/j.omton.2026.201274

Related articles

• Hepatotoxicity in the Era of Precision Medicine: Toxicological Mechanisms and Management of Immune and Cell Therapy‐Induced Liver Injury · MEDICINAL RESEARCH REVIEWS · 2026 · Cites or is cited by this article
• Rethinking lymphodepleting preconditioning in adoptive T cell therapy for durable tumor control · Molecular Therapy: Oncology · 2026 · Same journal
• Depletion of IL-10 in CAR-NK cells augments reprogramming of the tumor microenvironment and ameliorates therapeutic efficacy · Molecular Therapy: Oncology · 2026 · Same journal
• AGTR1 signaling contributes to tumor immunity and therapy response in non-small cell lung cancer · Molecular Therapy: Oncology · 2026 · Same journal
• Unmasking Wnt-driven HCC: Inhibiting SMYD2 to overcome immune resistance · Molecular Therapy: Oncology · 2026 · Same journal
• Intraperitoneal delivery of the oncolytic virus CF17 improves tumor immunogenicity and survival in gastric cancer peritoneal metastasis · Molecular Therapy: Oncology · 2026 · Same journal
• Synergistic Cell-Cycle Repression by HDAC/EZH2 Co-Targeting in H3K27-Altered Diffuse Midline Glioma · Molecular Therapy: Oncology · 2026 · Same journal
• Natural killer cell-derived extracellular vesicles reprogram cellular human immunity to enhance tumor cytotoxicity · Molecular Therapy: Oncology · 2026 · Same journal
• CAR design equips diverse immune cells with unique antigen-specific activation identities · Molecular Therapy: Oncology · 2026 · Same journal
• Optimizing CAR T cell therapy in pancreatic cancer through clinically actionable combinations · Molecular Therapy: Oncology · 2026 · Same journal